文献类型：期刊文献

英文题名：Chinese herbal medicine for primary dysmenorrhea: A systematic review and network meta-analysis of 54 randomized controlled trials

作者：Wang, Xinbin[1,3];Zhang, Zhongwen[1];Wang, Haorui[2];Ma, Ruilin[1];Wang, Lili[1];Zhang, Xianhui[1];Zhang, Yi[1];Wang, Rong[1]

第一作者：Wang, Xinbin;王新斌

通信作者：Wang, XB[1]

机构：[1]Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou, Peoples R China;[2]Fujian Univ Chinese Med, Sch Tradit Chinese & Western Med, Fuzhou 350108, Peoples R China;[3]35 Dingxi East Rd, Lanzhou, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), 35 Dingxi East Rd, Lanzhou, Gansu, Peoples R China.

年份：2023

卷号：63

外文期刊名：EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE

收录：;Scopus(收录号：2-s2.0-85171452318);WOS:【SCI-EXPANDED(收录号:WOS:001076302200001)】；

基金：This research was supported by Gansu Higher Education Innovation Fund (2021A-077) .

语种：英文

外文关键词：Primary dysmenorrhea; Chinese herbal medicine; Systematic review; Network meta-analysis

摘要：Introduction: Primary dysmenorrhea (PD) is a common gynecological complaint among adolescents and young women. Chinese herbal medicines (CHMs) have been widely used for PD treatment in China. However, the relative advantages of different CHM regimens remain uncertain. This systematic review aimed to compare the efficacy and safety of different CHMs for the treatment of PD using network meta-analysis.Methods: We searched PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Chinese BioMedical Literature Database (CBM) from their inception to December 17, 2022. Randomized controlled trials (RCTs) comparing CHM or Chinese patent drugs with Prostaglandin Synthetase Inhibitors (PGSIs) were included. Risk of bias was assessed using the Cochrane risk of bias tool. A frequentist framework network meta-analysis was performed using R (4.2.2).Results: A total of 54 RCTs with 5,345 PD patients were included. Compared with PGSIs, Danggui Sini decoction (mean difference [MD] =-5.92, 95% confidence interval [CI]-8.64 to-3.20) and Xiangfu Siwu Decoction (MD =-4.63, 95%CI-8.37 to-0.89) reduced pain significantly.; Danggui Sini decoction (risk ratio[RR] = 1.31, 95%CI 1.12 to 1.53), Danggui shaoyao san (RR = 1.23, 95%CI 1.05 to 1.44), Siwu decoction (RR = 1.32, 95%CI 1.17 to 1.47), Taohong Siwu Decoction (RR = 1.35, 95%CI 1.14 to 1.61), and Wenjing decoction (RR = 1.33, 95%CI 1.19 to 1.52) showed significantly higher overall response rates, and Wenjing decoction could significantly reduce TCM syndrome scores (MD =-4.14, 95%CI-6.84 to-1.44), compared with PGSIs. No serious adverse events were observed. Siwu decoction and Wenjing decoction ranked as the top treatment options in terms of all outcomes of interest (P-score ranking). Conclusions: CHMs were associated with improved overall response rate, pain reduction, and alleviation of symptoms compared to conventional treatments for patients with PD, and no serious adverse events were observed. However, the confidence in the conclusions is limited because of the lack of high-quality trials.